The NCL has just launched two new Technical Services to measure drug release from nanomedicines—ideal for assessing bioequivalence of complex drugs. These assays are available as a service to nanomedicine developers, apart from NCL’s Assay Cascade application process.
The two assays utilize the Stable Isotope Tracer Ultrafiltration Assay (SITUA), and include:
- In vitro drug release in human plasma
- A pharmacokinetic study in rats
The assay uses a stable isotopically labeled version of the drug and a simple ultrafiltration technique, allowing for easy measurement of plasma protein bound, unencapsulated and encapsulated nanomedicine fractions. (J Control Release, 2015, 220(Pt A), 169-174.)
Have questions or interested in the service? Contact the NCL team at email@example.com.